This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.
Laly Havern, PharmD, MS, BCACP
Advertisement
Articles by Laly Havern, PharmD, MS, BCACP
These agents are likely to become the mainstay of cancer treatment in the very near future.
Advertisement
Latest Updated Articles
Lower Discontinuation Rates on Cycled Oral Antineoplastics Can Lead to Lower Medical Costs, Fewer HospitalizationsPublished: February 7th 2023 | Updated:
Evaluation of a Pharmacy-Delivered Oncofertility InterventionPublished: June 11th 2025 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Dato-DXd Doubles Response Rates and Extends Survival in First-Line Metastatic TNBC
2
Emerging Biomarkers Open New Frontiers in Lung Cancer Therapy
3
Weekly Paclitaxel May Hold the Key to Pembrolizumab’s Success in Platinum-Resistance Ovarian Cancer
4
Final EMBARK Data Show “Almost Unprecedented” Reduction in Risk of Death With Enzalutamide Plus ADT in Biochemically Recurrent Prostate Cancer
5
